Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer

By Kalmadi Sujith   McNeill Giles   Davis Mellar   Peereboom David   Adelstein David   Mekhail Tarek  

Medical Oncology, Vol. 23, Iss. 4, 2006-12 ,pp. : 507-513

Humana Press, Inc

Access to resources Recommend Favorite

A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC)

By Raez Luis   Santos Edgardo   Webb R.   Wade James   Brito Roger   Karr Melissa   Kennah Andra   Childs Barrett  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 5, 2013-11 ,pp. : 1103-1110

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacogenetic Angiogenesis Profiling for First-Line Chemotherapy in Patients With Advanced Gastric Cancer

By Dan Su   Bai Li   Li-Jie Wang   Ting Zhang   Zhi-Yuan Mao  

Cancer Investigation, Vol. 31, Iss. 6, 2013-07 ,pp. : 390-396

Informa Healthcare

Access to resources Recommend Favorite

Phase I Trial of Carboplatin, Paclitaxel, Etoposide, and Cyclophosphamide with Granulocyte Colony Stimulating Factor as First-Line Therapy for Patients with Advanced Epithelial Ovarian Cancer

By Tung N.   Berkowitz R.   Matulonis U.   Quartulli M.   Seiden M.   Kim Y.   Niloff J.   Cannistra S.A.  

Gynecologic Oncology, Vol. 77, Iss. 2, 2000-05 ,pp. : 271-277

Elsevier

Access to resources Recommend Favorite

A Phase I Study Of Docetaxel, Oxaliplatin, & Capecitabine (DOC) As First-Line Therapy of Patients With Locally Advanced or Metastatic Adenocarcinoma of Stomach and GE Junction

By Malik Imtiaz   Bernal Pedro   Byrd Janet  

Cancer Investigation, Vol. 28, Iss. 8, 2010-09 ,pp. : 833-838

Informa Healthcare

Access to resources Recommend Favorite